Kronox Lab Sciences Ltd has finalized a 64.26% stake transfer to Indo Borax & Chemicals Limited. The transaction has triggered a complete overhaul of the Board of Directors and senior leadership team, effective September 29, 2026. The outgoing promoters will remain involved for 36 months under consultancy agreements to ensure a structured operational handover.
Kronox Lab Sciences Undergoes Major Ownership and Board Transition
64.26% equity stake transferred to Indo Borax & Chemicals Limited.
Total leadership overhaul including new MD, CEO, and CFO appointments effective September 29, 2026.
Reader Takeaway: Ownership change signals a new strategic direction, while consultancy pacts aim to mitigate transition-related operational risks.
What just happened
Kronox Lab Sciences Ltd has officially transitioned majority ownership, with 2,38,44,000 equity shares moving to Indo Borax & Chemicals Limited. This change in control has resulted in a wholesale replacement of the company's leadership and board of directors. Key positions including the Managing Director, CEO, and CFO have been filled by new appointees, while all previous promoters and executive directors have stepped down.
Why this matters
The change represents a complete shift in corporate governance and strategic oversight. The appointment of a fresh board and executive team indicates that Indo Borax & Chemicals will likely implement a new operating philosophy at Kronox Lab Sciences. The market will now pivot its focus toward the performance track record of the incoming leadership and their ability to integrate the business under the new ownership structure.
The backstory
The outgoing promoters—Mr. Jogindersingh G. Jaswal, Mr. Ketan Ramani, and Mr. Pritesh V. Ramani—have exited their executive roles. To ensure business continuity, the company has signed 36-month consultancy agreements with each of them, involving a fixed fee of Rs 2.10 crore per person. These agreements focus on R&D, production, and quality control, and include a 24-month lock-in period.
What changes now
The company has fully reconstituted its primary board committees, including the Audit, Nomination and Remuneration, Stakeholders Relationship, and CSR committees. This ensures the new team has immediate control over governance and financial oversight functions.
Risks to watch
The primary risk for retail investors is the operational impact of a complete leadership vacuum during the transition. While consultancy agreements provide a buffer for R&D and production, the execution risk remains high as the company shifts to new management mandates.
What to track next
Watch for the upcoming corporate strategy announcement from the new board and any changes to capital expenditure or dividend policies that may follow this shift in control.